Is Biotech risky business? I think we can all agree due to the research and development and the unknown areas as far as predicting a winner can be close to a roll of the dice at times. The bar has risen a bit today to secure VC funds no doubt and then we still hear about the failed trials...
More additional affiliations for the FDA to gather information. In the news recently have been other agreements with companies such as Blue Cross and others who will be providing data to also study the effects of drugs through medical record information in their files, based on claims, etc. No...
Patrice Milos, Vice President and Chief Scientific Officer, Helicos Biosciences This week I had the opportunity to talk with Patrice Milos from Helicos Biosciences who has a long background in global research and spent a number of years at Pfizer as Executive Director at Pfizer Global Research and Development...
It should be the discretion of individual physicians, not insurance companies or pharmacies, to substitute a branded biologic for a biosimilar, which goes back to putting the physician in the decision making process, not the non clinical analyzers. While the search for "cheap" continues...
Right now according to the Wall Street Journal, patients who have enjoyed an open relationship are worried that this could all change under management from Roche. Is bigger always better? Recently in the news Genentech is not happy with the offer and may hold out for more. Anyone that...
Discussed here is the recent law in Massachusetts relative to gifts, etc. just recently passed. Being the CEO of BIO, the biotech industry trade group, of course there's an interest in not having funds diminished, but also addresses the interest of the public. With all the recent Pharma...
An interesting story on what a DNA report can reveal, in this case the woman has an X and a Y, instead of two Xs, like most females. It is somewhat rare but does exist with having internal testicles, and this produces extra high levels of estrogen, the the testosterone produced pretty much can't...
A new possible term in the world of Biotech, Biogenerics? We currently have Pharmacogenomics working and now perhaps an interest with the Generic Drug business investing in Biotech as well or perhaps the availability of a generic without a long patent protection period? I am not quite sure...
Mark up one more purchase for Roche this week. Pharmaceutical companies are looking for for biotech purchases and Roche is not wasting one moment this week. Arius fits right in with current ongoing cancer research. Who will be on the list tomorrow? BD Roche announced this...
The cardiovascular point of care tests will be marketed by Roche Diagnostics. The test will located elevated levels of the markers for BNP, which are indicators for heart failure. A very sophisticated technology that will allow for hospitals to check with a simple test to see if a patient...